AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00003282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EF5
Description: Given IV
Study NCT00003282 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo resection
Study NCT00003282 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Undergo biopsy
Study NCT00003282 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT04609215 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ALECSAT
Description: Patients will receive concurrent chemotherapy with carboplatin/gemcitabine with cycles repeated every 3 weeks.~During the loading phase, patients will receive ALECSAT at 28 days intervals at weeks 5, 9, and 13. Hereafter (the maintenance phase), ALECSAT will be administered every 12 weeks until disease progression, death, unacceptable toxicity, investigator/patient decision or EOT visit at 18 months.
Study NCT02516345 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentives
Description: Incentives will be awarded to participating children for meeting step targets as measured by the Fitbit pedometer.
Study NCT03949374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CRESTOR, reference formulation of rosuvastatin
Description: Use of ROVASRO for hypercholesterolemia
Study NCT03949374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ROVASRO, generic formulation of rosuvastatin
Description: Use of CRESTOR for hypercholesterolemia
Study NCT04483271 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 300 mg of omega3-FA
Description: The participant will receive 1,000 mg of wild salmon and fish oil complex once daily, which contains 300 mg of omega3-FA.~Baseline and follow-up serum levels of IL-1,IL-6, and TNF will be measured.
Study NCT00622245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AA34893
Description: per oral doses, divided in twice daily administrations as capsules, during 12 weeks, followed by a one-week tapering period
Study NCT00622245 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Quetiapine fumarate
Description: per oral, once daily, during 12 weeks, followed by a one-week tapering period
Study NCT00622245 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: per oral doses, twice daily as capsules during 13 weeks
Study NCT02536196 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embolic Protection Device
Description: Embolic protection
Study NCT02536196 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcatheter aortic valve implantation (TAVI)
Description: Transcatheter aortic valve implantation (TAVI)
Study NCT02536196 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Description: Transcatheter aortic valve implantation (TAVI)
Study NCT02031354 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lysine Chloride
Description: Administration of 21g of lysine chloride (7g three times daily) for a period of time of 3 days
Study NCT04481932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab combined with Pyrotinib and chemotherapy
Description: Pyrotinib is a small molecule, irreversible tyrosine kinase inhibitor with targets of epidermal growth factor receptor 1 (EGFR/HER1/ErbB1), human epidermal factor receptor 2 (HER2/ErbB2/Neu) and human epidermis Factor Receptor 4 (HER4/ErbB4).~As a new generation of anti-HER2 therapeutic targeted drugs, pirotinib covalently binds to the ATP binding sites of the kinase regions of EGFR, HER2 and HER4 in cells to prevent homogeneity and heterogeneity of EGFR, HER2 and HER4 in tumor cells Dimer formation, inhibiting its own phosphorylation, blocking the activation of downstream signaling pathways, thereby inhibiting tumor cell growth
Study NCT01211002 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy combined with EP
Description: Tumor vo lume is 60-66 Gy / 30-33f and the combination regimen is etoposide (50 mg/m2 day1-5, 29-33) and cisplatin (50 mg/m2 day1, 8, 29, 36) in the 1st, 4th weeks of radiotherapy for 2 courses.
Study NCT01211002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: radiotherapy / EP combined with recombinant human endostatin
Description: Anti-vascular targeting therapy The number of courses is 3 \~ 4 and each course last for 28 days. Recombinant human endostatin（Endostar）：15mg，d1-14, intravenous injection.
Study NCT03370601 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Infliximab
Description: Infliximab 10mg/kg every 8 weeks
Study NCT03370601 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mercaptopurine
Description: 6-mercaptopurine 1 à 1,5 mg/kg
Study NCT03370601 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Azathioprine
Description: Azathioprine 2 à 2.5mg/kg/j
Study NCT03370601 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Infliximab
Description: Infliximab 5mg/kg every 8 weeks
Study NCT03782792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Solution for infusion
Study NCT03782792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Solution for infusion
Study NCT00645060 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high performance liquid chromatography
Description: Performed on serial blood samples from 0 to 168 hours and daily X5 days 24 hour urine samples
Study NCT00645060 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Serial blood samples from 0 to 168 hours and daily X5 days 24 hour urine samples
Study NCT00645060 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radionuclide imaging
Description: 1-3 hours, 1 day, 2 days, 3-5 days and 6-7 days post Y-90 anti-CEA antibody infusion
Study NCT00645060 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single photon emission computed tomography
Description: 2 days and 3-5 days post antibody infusion
Study NCT00645060 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A
Description: Dose escalation from 12 mCi/m2 through 18 mCi/m2 increasing by 2 mCi/m2 with each escalation
Study NCT01927874 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infiltration
Description: injection of local anesthetic, associated with general anesthesia
Study NCT01927874 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal block
Description: injection of anesthetic
Study NCT01927874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 10ml 0.5% bupivacaine.
Study NCT01927874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 mg of hyperbaric 0.5% bupivacaine
Description: Spinal punction and injection of local anesthetic
Study NCT01280175 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: charcoal block
Study NCT01280175 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aerochamber Plus spacer
Study NCT01280175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pMDI standard actuator
Study NCT02187133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given IV; Dose Level (DL)~Twice Weekly:~DL -1 and DL 1: 15 mg/m\^2~Weekly:~DL 1.5: 20,27,27 mg/m\^2, DL 2: 20,36,36 mg/m\^2, DL 3: 20,56,56 mg/m\^2 DL 4: 20,70,70 mg/m\^2
Study NCT02187133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Given IV; Dose Level (DL)~DL -1: 75 mg/m\^2 DL 1,1.5, 2, 3, and 4: 90 mg/m\^2
Study NCT01678911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gralise
Description: Subjects will start at 600mg and titrate up by 600mg a week for two weeks (to 1800mg), then remain on 1800mg steady state dose of medication (or placebo pills) for 2 weeks. If intolerable side effects occur, the dose may be reduced to last tolerable dose at the discretion of the PI. A 2-week down-titration will be used. Subjects will have 1 week of wash-out before repeating the above procedure for the other arm of the study (placebo or medication).
Study NCT02187133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV; 375 mg/m\^2
Study NCT04358991 — intervention group
Intervention type: DRUG
Intervention: Ceftazidime-avibactam
Description: collection of blood samples around clinical dosing immediately pre-dose, then at the following times thereafter: 1, 2, 4, 6, 8, and 12 hours and EMR review.
Study NCT02564562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] PF-06463922
Description: Single oral dose of 100mg PF-06463922 + \[14C\] PF-06463922
Study NCT00574366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: Levels:~* 1 Erlotinib 50 mg/d~* 2 Erlotinib 50 mg/d~  * 1 Erlotinib 100 mg/d~ * 2 Erlotinib 100 mg/d~ * 3 Erlotinib 150 mg/d~ * 4 Erlotinib 150 mg/d
Study NCT00574366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Levels~minus 1: RAD001 2.5 mg/d~minus 2: RAD001 2.5 every other day~1. RAD001 2.5 mg per day~2. RAD001 5 mg per day~3. RAD001 10 mg per day~4. RAD001 10 mg per day
Study NCT02647892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine
Description: local anesthesia
Study NCT02647892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium bicarbonate
Description: additional drug added to lidocaine
Study NCT01000805 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received placebo QD, po for 8 weeks.
Study NCT02910973 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vagus Nerve Stimulation
Description: Patients will receive transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes. Blood will be withdrawn prior to stimulation and 1 hour following the stimulation. The device is a handheld electrical pulse generator and a pair of electrodes to be placed at the ear for stimulation. The specific target at the ear will be the auricular branch of the vagus nerve which innervates the skin of the ear canal. Electrodes will be placed near/at the entrance to the canal of the ear to provide stimulation to the auricular branch of the vagus nerve.
Study NCT01849562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sovaprevir
Description: Nonstructural protein 3/4A protease inhibitor.
Study NCT01849562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACH-3102
Description: Nonstructural protein 5A inhibitor.
Study NCT01849562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Study NCT01849562 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02556580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin 20%
Description: Intervention: intravenious infusion Drug: albumin
Study NCT02556580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin 20%
Description: Intervention: intravenious infusion Drug: albumin
Study NCT04216667 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation
Description: Catheter ablation
Study NCT04216667 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Description: Catheter ablation
Study NCT04278716 — intervention group
Intervention type: OTHER
Intervention: Safe return to play checklist
Description: this objective checklist will be utilized by the physical therapy staff and surgeon to determine whether an athlete is safe to return to their sport
Study NCT04444674 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19
Description: Dose of 5-7.5x10\^10vp of ChAdOx1 nCoV-19
Study NCT04444674 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline 0.9%
Description: Normal saline 0.9% as placebo
Study NCT00700349 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Small loan
Description: Applicants in the treatment group were offered an interest rate, loan size, and maturity per the lender's standard underwriting criteria, involving a 4-month maturity at 11.75% per month, charged on the original balance (200% annual percentage rate).
Study NCT00574392 — intervention group
Intervention type: DEVICE
Intervention: Multiwavelength and coherence confocal reflectance microscopy (Vivascope 1500m multiwavelength)
Description: Patients will be imaged with the Vivascope 1500m multiwavelength coherence microscope during a single patient visit. The lesion will be photographed with high resolution photography and surface epiluminescence microscopy. The clinically uninvolved site will be imaged in the same manner.
Study NCT00236210 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Action Score
Description: Improvement in a novel 100-point score summarizing cardiovascular risk.
Study NCT03772795 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Orthodontic Alignment
Description: Group 1:- Teeth alignment in this group started using round 0.014 NiTi arch wire. The 0.014 NiTi arch wire was placed into the slots of the brackets and tied with elastomers by figure of 8. During this stage, only tipping movement was applied.
Study NCT03772795 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orthodontic Alignment
Description: Group 2: Teeth alignment using clear aligners.
Study NCT02356523 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Confusion Assessment Method
Description: Administration of Confusion Assessment Method at patent over 65 years at admission and every day until discharge
Study NCT01823198 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given SC
Study NCT01823198 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic CD56-positive CD3-negative Natural Killer Cells
Description: Given IV
Study NCT01823198 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic PBSC transplant
Study NCT02910973 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Vagus Nerve Stimulation
Description: Patients will receive sham transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes. Blood will be withdrawn prior to stimulation and 1 hour following the stimulation. Sham stimulation will be performed in the identical manner as true transcutaneous stimulation except that the patient will not receive electrical stimulation of the vagus nerve.
Study NCT03411174 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated partial breast irradiation
Description: deliver 40Gy/15Fx to tumor bed areas
Study NCT04756440 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education Program and Music Therapy
Description: After the intervention, it is expected that their awareness of Romana cervical cancer will increase, their perception of obstacle towards screening tests will decrease and they will be tested.
Study NCT03959384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curosurf 80Mg/Ml Intratracheal Suspension
Description: CUROSURF is a natural surfactant obtained from swine lungs containing almost exclusively phospholipids, in particular phosphatidylcholine (about 70% of the total phospholipid content) and about 1% of low molecular weight hydrophobic proteins, specific for surfactant, SP-B and SP -C. CUROSURF will be administered via endotracheopulmunary.
Study NCT03959384 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ambient Air
Description: Ambient air aspirated in sterile syringes
Study NCT04474496 — intervention group
Intervention type: OTHER
Intervention: Assessing the impact of COVID-19
Description: Surveying Marshallese adults in the U.S. to determine the impact of COVID-19
Study NCT04453332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral hormone therapy (estradiol and micronized natural progesterone)
Description: Oral hormone therapy - estradiol 1mg every day and micronized natural progesterone 200mg only 14 days a month
Study NCT04453332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-oral hormone therapy (estradiol and micronized natural progesterone)
Description: Percutaneous estradiol gel 1.5mg every day and micronized progesterone 200mg vaginal only 14 days a month
Study NCT00236210 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VIP program
Description: Risk assessment, lifestyle counselling, exercise program
Study NCT04371913 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: 600cGY x 5 fractions
Description: Patients will be treated with the fractionation of 30 Gy in 5 fractions over 1-2 weeks, which is the accelerated fractionation scheme of choice for RT naïve patients at New York Presbyterian using EBRT.
Study NCT00877760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated interferon a-2a
Description: 180 μg, once per week s.c. for 24 weeks
Study NCT00877760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: 0.5 mg once daily per os, either 72 weeks or 96 weeks
Study NCT00877760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: 0.5 mg once daily per os, either 72 weeks or 96 weeks
Study NCT00991367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cicatrix
Description: Dosage commensurate with surface to be treated. After washing and drying the affected area, a thin layer of CICATRIX (Topical use) will be applied on the lesion rubbing in different directions for 2 minutes, three times a day, for 4 weeks.
Study NCT00991367 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage commensurate with surface to be treated. After washing and drying the affected area, a thin layer of PLACEBO (Topical use) will be applied on the lesion rubbing in different directions for 2 minutes, three times a day, for 4 weeks.
Study NCT02468804 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: TMS: Repetitive TMS will be administered using a 70-mm diameter air-cooled figure-of-8 coil and SuperRapid2 Stimulator (Magstim, Jali Medical US distributors, Woburn, MA). Repetitive pulses will be delivered to the right and left pre-frontal cortex (Brodman area 46) using a frameless stereotactic navigation system and the subject's MRI in Brainsight software. Stimuli will be delivered at 20 Hz at 90% of the subjects resting motor threshold (rMT) for 25 trains of 30 pulses per train, inter-train interval of 30 seconds for a total of 750 pulses per hemisphere. The same TMS parameters as active stimulation but with the coil held at 90° to the scalp to induce similar somatic sensations and noise as in the active group with minimal direct brain effects.
Study NCT02468804 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TMS
Description: Sham TMS will be administered with a Magstim sham coil with electrodes attached to mimic the sounds and sensation of real TMS. The site and frequency of stimulation will be identical to the real TMS described above.
Study NCT03228849 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture anchor technique
Description: Suture anchors were used to attach bony fragment. On week 6, patients were then started on physical therapy for 2 weeks.
Study NCT03228849 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative Treatment
Description: The injured finger was immobilized in an aluminium splint for 6 weeks. Patients were then started on physical therapy for 2 weeks.
Study NCT01759693 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sampling
Description: Blood sampling
Study NCT02094625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: NAC will be administered intravenously over \~60 minutes starting 4 hours following completion of cisplatin chemotherapy.~Three dose levels have been pre-determined:~Dose Level 1: 225 mg/kg Dose Level 2: 300 mg/kg Dose Level 3: 450 mg/kg~Should Dose Level 3 exceed the MTD, the study will examine blood levels of NAC and if below the target blood level necessary for hearing protection, the study will de-escalate from Dose Level 3 to an intermediate Dose Level 2.5 and test a dose of 375 mg/kg.~As of August 2018: Dose escalation completed with MTD not reached. Dose level 3 (450mg/kg) selected for expansion with NAC.
Study NCT01060722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOD-4023 (long lasting hGH)
Description: Single subcutaneous dose of MOD-4023
Study NCT01060722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single subcutaneous dose of placebo material
Study NCT00209092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Sequential Therapy: Docetaxel will be given at 100 mg/m\^2 Intravenously (IV)Day 1 every 3 weeks for 4 cycles.~Concurrent Therapy: Docetaxel will be given at 50 mg/m\^2 IV Day 1.
Study NCT00209092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Sequential Therapy: administration of capecitabine 1000 mg/m\^2 twice a day by mouth Day 1-14 every 3 weeks for 4 cycles (total 8 cycles) Concurrent Therapy: capecitabine 1000 mg/m\^2 twice a day by mouth Day 1-7 every 2 weeks for 8 cycles (total 16 weeks).
Study NCT00521118 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00521118 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo second curettage